DRUG · Mapped RxNorm record
insulin degludec
Normalized identity: insulin degludecView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
NCT01079234
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
insulin glargine
Normalized identity: insulin glargineView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
insulin aspart
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedComparison of NN1250 With Insulin Glargine in Type 1 Diabetes
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Diabetesverified · MONDO: diabetes mellitus
Interventions
insulin degludecDRUG · verified · RxNorm: insulin degludec
insulin glargineDRUG · verified · RxNorm: insulin glargine
insulin aspartDRUG
Sponsors & collaborators
Novo Nordisk A/Slead sponsor
Mapped research locations
DallasTexas, United States3HamburgGermany3AthensGreece3ThessalonikiGreece2Des MoinesIowa, United States2HoustonTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1MiamiFlorida, United States1AuroraColorado, United States1DenverColorado, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01079234 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.